Pharma's Second Act in Puerto Rico Looks Nothing Like the First

To understand where Puerto Rico pharmaceutical manufacturing is going, it helps to be honest about what happened last time.

The first era was enormous. For decades the island was one of the most important pharmaceutical production centers anywhere, driven substantially by a US federal tax provision that made manufacturing there extraordinarily attractive. Plants went up. Employment climbed. A generation of islanders built careers inside multinational quality systems.

Then the federal provision was phased out, and a lot of that activity left.

That is the part of the history that local conversation sometimes skips, and skipping it is a mistake, because the contraction is exactly what makes the current phase interesting.

What stayed, and why it matters

Not everything left. What remained was, broadly, the work that was hardest to move.

Complex sterile manufacturing stayed. Biologics capability grew. Operations with deep regulatory history and validated processes that would be expensive and risky to relocate stayed put. And critically, the workforce stayed — or at least enough of it did that the capability did not evaporate.

That filtering produced something more durable than what preceded it. An operation that survived the loss of its original tax rationale is, by definition, there for other reasons: process complexity, regulatory inertia, talent, or genuine operational fit.

Those reasons do not expire on a legislative schedule.

The biologics shift changed the geography

The single most important technical development for Puerto Rico's pharmaceutical future is the industry's move toward large molecule products.

Small molecule manufacturing is relatively portable. The process is well characterized, the technology transfer is understood, and moving production between qualified sites is a known exercise. That portability is precisely why so much small molecule work migrated over the years.

Biologics do not behave this way. In large molecule production the process substantially determines the product. Change the site, the scale, or a key input, and you have a development and comparability exercise rather than a transfer. That stickiness cuts both ways: it is hard to bring biologics to a site, and once there, hard to take away.

For Puerto Rico this is structurally favorable. Biologics capacity on the island tends to stay, and it brings development activity with it, because you cannot run a modern sterile biologics operation on operational staff alone. You need process science, analytical development, characterization and stability capability near the line.

That is research activity, and it does not get repatriated in a budget cycle.

The policy environment, without overstatement

Supply chain disruption taught the pharmaceutical industry and its regulators that resilience had been underpriced. The policy response has favored production under domestic control.

Puerto Rico's position in that conversation is unusual: fully domestic for regulatory, legal and supply security purposes, already built for pharmaceutical manufacturing, and cost competitive against a continental site.

It is worth being measured about this. Policy interest is not the same as policy certainty, and companies should not build a capital plan on the assumption that a particular incentive or preference will exist in a decade. But the structural case — domestic, capable, cheaper — does not depend on any specific policy surviving.

Where the incentives fit now

Puerto Rico's current framework is Act 60-2019, which consolidated the earlier statutes including Act 73-2008 (Legacy). For research activity, §3030.01 provides the credit, modeled at two fixed rates: 50 percent on direct R&D investment deployed in Puerto Rico into experimental activities, and 20 percent on indirect investment deployed outside Puerto Rico or into incidental activities.

For a pharmaceutical operation this tends to be more relevant than finance teams expect, because so much of modern pharmaceutical work is genuinely experimental. Process characterization. Analytical method development and validation. Formulation and API route development. Comparability studies. Scale-up investigation where the behavior at production scale is not known in advance.

These are not routine activities relabeled. They are the substance of pharmaceutical development, and a significant portion of them happen on the island.

What does not qualify is equally clear: running a validated process to make product, routine release testing against established methods, and routine stability monitoring on an approved product.

The structural caveat for US-parented groups

If the Puerto Rico entity sits under a US parent, the decree rate is one layer of the group's position rather than a worldwide outcome. The subsidiary is generally a controlled foreign corporation for US federal purposes, which brings its own analysis, and large groups also face global minimum tax considerations.

We say this plainly because tax directors ask it first, and a site that does not address it looks either naive or evasive.

Everything in this article is indicative advisory context. Your position depends on your decree, your structure and your facts, and should be confirmed before you plan around it.

What to watch

The metric that tells you whether this second act is real is not announced capital. It is headcount mix.

If Puerto Rico pharmaceutical sites keep adding process scientists, analytical chemists and development engineers faster than they add line operators, the island has genuinely moved up the value chain. If the mix flattens, it is a manufacturing story with a better tax position, which is fine but less interesting.

Right now the mix is moving in the right direction, which is the most encouraging thing you can say about an industry that has been through one full cycle on this island already.